REPORT HIGHLIGHT
Inflammatory Bowel Disease (IBD) Treatment market was valued at USD 15.87 billion by 2019, growing with 4.1% CAGR during the forecast period, 2020-2026
Market Dynamics
A rise in the number of drugs available in clinical tests, growing prevalence of inflammatory bowel disease (IBD), and rising government initiatives related to the analysis of the causes and effective novel drug developments are the major factors driving the growth of global IBD treatment market. In addition, the high prevalence of and growing occurrence of ulcerative colitis and Chron's disease are likely to create growth opportunities in the IBD treatment market in the projected timeframe. However, stringent drug regulatory policies and lack of treatment effectiveness are predicted to impede the market growth in the coming future.
Types Takeaway
The Crohn’s disease type segment accounted for the majority of share in 2019 and is expected to rise at an impressive growth rate during the forecast period. This growth is primarily owing to the growing prevalence of the condition. As per a published article in 2018 in Jobson Medical Information LLC, the occurrence of Chron’s disease was found to be approximately 3.1 to 14.6 cases per 100,000 people each year and the incidence in the U.S. was around 201 cases per 100,000 adults. On the other hand, the ulcerative colitis segment is expected to grow at the fastest rate throughout the forecast majorly due to presence of strong pipeline for the treatment of ulcerative colitis.
Route of Distribution Takeaway
The injectables route of administration segment is considered to be the largest due to its efficacy. Additionally, the development of biosimilars such as Inflectra is likely to boost the segmental market growth. Along with injectables, the oral route segment is projected to be the fastest-growing market by 2030 owing to the presence of strong pipeline products. The ASAs sub-segment of the oral route of administration subjugated the market in 2019 and the AK inhibitors sub-segment is estimated to grow at the fastest pace during the period of forecast.
Distribution Channel Takeaway
By distribution channel, the hospital pharmacy segment including both out-patient and in-patient subjugated the market in 2018 and is predicted to grow exponentially throughout the forecast. This is majorly owing to the rising prevalence of ulcerative colitis and Crohn’s disease coupled with a growing total number of hospitalizations all across the globe. On the other hand, the online pharmacy is predicted to be the fastest-growing segmental market by the end of 2030. The increasing demand and rising trend of online purchasing are contributing to the growth of online pharmacy segment. In addition, customers find online pharmacy beneficial due to the availability of various offers and discounts.
Regional Takeaway
Presently, the North America market for IBD treatment is playing a dominant role owing to the presence of major market players and sophisticated healthcare infrastructure. The region is expected to lead the market during the period of forecast due to rising prevalence of Chron’s diseases & ulcerative colitis and the growing increasing geriatric population in the U.S. On the other hand, the Asia Pacific region is estimated to grow at the fastest pace by the end of 2030 due to increasing product approvals in this region.
Key players of the market include:
• Pfizer Inc.
• AbbVie Inc.
• Cosmo Pharmaceuticals
• UCB S.A.
• Innovate Biopharmaceuticals
• Gilead Sciences
• Celgene Corporation
• Celltrion Healthcare Co., Ltd.
• Johnson & Johnson Services Inc.
• Takeda Pharmaceutical Company Limited
The market size and forecast for each segment and sub-segments has been considered as below:
• Historical Year – 2015 to 2018
• Base Year – 2019
• Estimated Year – 2020
• Projected Year – 2026
TARGET AUDIENCE
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
? Oral
o 5-Aminosalicylic Acid
o Corticosteroids
o Janus Kinase (JAK) Inhibitors
o Others
? Injectable
o Tumor Necrosis Factor (TNF) Inhibitors
o Interleukin inhibitors
o Anti-integrin
o Others
GLOBAL INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT MARKET, BY TYPE
? Chron’s Disease
? Ulcerative Colitis
? Others
GLOBAL INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
? Retail Pharmacy
? Hospital Pharmacy
? Online Pharmacy
? Others
GLOBAL INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT MARKET, BY REGION
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA